Sun.May 26, 2024

article thumbnail

Pegcetacoplan Offers Potential Benefit in Post-Transplant C3G, IC-MPGN

HCPLive

The phase 2 NOBLE trial shows pegcetacoplan reduces disease activity in post-transplant C3G and IC-MPGN, with benefits persisting through the 40-week double-blind period.

article thumbnail

The possible mechanism and research progress of ACE2 involved in cardiovascular injury caused by COVID-19: a review

Frontiers in Cardiovascular Medicine

ACE2 is the earliest receptor discovered to mediate the entry of SARS-CoV-2. In addition to the receptor, it also participates in complex pathological and physiological processes, including regulating the RAS system, apelin, KKS system, and immune system. In addition to affecting the respiratory system, viral infections also interact with cardiovascular diseases.

COVID-19 106
article thumbnail

Survey: how women (and our doctors) respond to early cardiac symptoms

Heart Sisters

Female heart patients would love to believe that all cardiologists are "extremely well prepared" to assess our cardiovascular risks - but is that true?

Education 104
article thumbnail

Association of stress hyperglycemia ratio with left ventricular function and microvascular obstruction in patients with ST-segment elevation myocardial infarction: a 3.0 T cardiac magnetic resonance study

Cardiovascular Diabetology

Stress hyperglycemia, which is associated with poor prognosis in patients with acute myocardial infarction (AMI), can be determined using the stress hyperglycemia ratio (SHR). Impaired left ventricular functio.

article thumbnail

Iptacopan Reduces Proteinuria, Demonstrates Benefit in C3 Glomerulopathy

HCPLive

In the APPEAR-C3G trial, iptacopan reduced proteinuria by 35.1% in patients with C3 glomerulopathy, with Novartis planning regulatory submissions for C3G before the end of 2024.

72
article thumbnail

Causal role of immune cells in hypertension: a bidirectional Mendelian randomization study

Frontiers in Cardiovascular Medicine

BackgroundAlthough Hypertension (HTN) is considered to be a cardiovascular disease caused by multiple factors, the cause of it is still unknown. In this study, we aim to find out whether circulating immune cell characteristics have an impact on susceptibility to HTN.MethodsThis study employed a comprehensive two-sample Mendelian randomization (MR) analysis to investigate the causal association between immune cell characteristics and HTN.

article thumbnail

SELECT Analysis: Semaglutide 2.4 mg (Wegovy) Reduces Negative Kidney Outcomes

HCPLive

Semaglutide 2.4 mg reduces kidney events in SELECT participants, showing renoprotective effects in addition to cardiovascular benefits.

More Trending

article thumbnail

Just Hours Left

Dr. Paddy Barrett

If you are like me, you probably wait until the very last minute to take up an offer. Loads of you have taken the opportunity to get access to the Heart Health Express. I hope you are enjoying it. After today, the Heart Health Express version will not be available for purchase. Likely ever. In the future, the EXPRESS course will likely be included as part of the Complete Heart Health Formula.

52
article thumbnail

Helen Colhoun, MD: Semaglutide 2.4 mg (Wegovy) Reduces Kidney Outcomes in SELECT

HCPLive

Helen Colhoun, MD, discusses the results of a SELECT analysis she presented at the 61st European Renal Association Congress.

article thumbnail

How many molecules of LDL enter the coronary vascular endothelium per day ?

Dr. S. Venkatesan MD

LDL is potrayed as villian de-chief of atheroscerlois and CAD.But, LDL of about 100 to 160 mg concentration is in constant circulation, in a smooth manner serving other physiological vascular functions. The force of evidence that LDL can pierce an Intact endothelium is so huge no one can has the courage to dispute.But, it doesnt happen in majority is the mysterious truth.

article thumbnail

David Kavanagh, MBChB, PhD: Iptacopan Offers Hope for C3 Glomerulopathy

HCPLive

A Q&A with David Kavanagh, MBChB, PhD, on the results of the APPEAR-C3G trial and implications for care moving forward.

52
article thumbnail

Burden of cardiovascular disease on coronavirus disease 2019 hospitalizations in the USA

Coronary Artery Disease Journal

Background Patients with cardiovascular disease (CVD) and risk factors have increased rates of adverse events and mortality after hospitalization for coronavirus disease 2019 (COVID-19). In this study, we attempted to identify and assess the effects of CVD on COVID-19 hospitalizations in the USA using a large national database. Methods The current study was a retrospective analysis of data from the US National (Nationwide) Inpatient Sample from 2020.

article thumbnail

High Price of Popular Diabetes Drugs Deprives Low-Income People of Effective Options

Med Page Today

(MedPage Today) -- For the past year and a half, Tandra Cooper Harris and her husband, Marcus, who both have diabetes, have struggled to fill their prescriptions for the medications they need to control their blood sugar. Without semaglutide.

Diabetes 122